Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2013-02-16

FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Fresenius Kabi USA, LLC)

View source ↗

Summary

The FDA approved a supplemental application for Levothyroxine Sodium (levothyroxine sodium anhydrous) from Fresenius Kabi USA, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVOTHYROXINE SODIUM (levothyroxine sodium)

Snippet

SUPPL AP for LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM ANHYDROUS)